Dr. Carol Curtis received her bachelor’s in biochemistry, and her masters and doctorate in molecular and integrative physiology from the University of Illinois at Urbana-Champaign. She spent 4 years as a postdoctoral researcher at the Oklahoma Medical Research Foundation before joining the preclinical stage biotech firm, EpimedX. While working for EpimedX and then as a consultant to 5 additional biotech startup companies, Dr. Curtis managed operations, supervised scientific projects, interacted with the FDA, wrote grants to secure funding, and worked closely with investors. Dr. Curtis was critical in securing over $0.8M in non-dilutive funding to support preclinical research and development efforts at EpimedX and Jortan Pharmaceuticals.
Dr. Curtis joined i2E in 2015 and has provided venture advisory services to 30+ clients across multiple life sciences and tech-based industries positioning these companies for potential funding from i2E managed funds. She has evaluated more than 20 companies in preparation for investment and has closed over $15M in equity financings while at i2E. Dr. Curtis led i2E investments in Otologics Pharmaceuticals, SendaRide, Whiteboard, Digital 6 Labs, and Tetherex.
In addition to formal education, Dr. Curtis has continued education in project management, financial modeling, bioscience business and biotechnology entrepreneurship, and venture deals as well as advanced training in building start-ups. Dr. Curtis has published numerous peer-reviewed papers and sits on several advisory boards.